This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Emmaus Medical, Inc.
Drug Names(s): levoglutamide, PGLG, L-glutamine, Pharmaceutical Grade L-glutamine
Description: The patented drug treatment involves the oral administration of L-glutamine, an amino acid. L-glutamine is required in the last step of NAD synthesis, where it is an amide donor for NAD synthetase. Increasing glutamine in sickle cells should increase NAD. The ratio of NAD/(NAD+ and NADH) is decreased in sickle cells. This causes a reduced redox potential and increased 2,3-DPG (diphosphoglycerate), which may be responsible for the sickling.
Deal Structure: This oral version of L-glutamine was developed at the Los Angeles Biomedical Research Institute (LA BioMed) and licensed to Emmaus Medical.
Additional information available to subscribers only: